Overview

Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - EFTISARC-NEO Trial

Status:
Recruiting

Trial end date:
2027-04-30

Target enrollment:

Participant gender:

Summary

This is a phase II single-arm single-stage study evaluating efficacy and safety of pembrolizumab in combination with a soluble LAG-3 protein, eftilagimod alpha (Efti) and radiotherapy in neoadjuvant treatment of patients with soft tissue sarcomas. This study will determine the pathologic response rate (defined as percentage of tumor hyalinization/fibrosis) to the combination treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Maria Sklodowska-Curie National Research Institute of Oncology

Collaborator:

Immutep S.A.S.

Treatments:

Pembrolizumab